medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2016, Number 2

<< Back Next >>

Rev Invest Clin 2016; 68 (2)

The Role of Immunosenescence in the Development of Age-Related Diseases

Fülöp T, Dupuis G, Witkowski JM, Larbi A

Language: English
References: 90
Page: 84-91
PDF size: 93.58 Kb.


ABSTRACT

Aging is a complex phenomenon leading to numerous changes in the physiological systems of the body. One of the most important changes, called immunosenescence, occurs in the immune system. Immunosenescence covers changes in the innate and the adaptive immune systems and is associated with a low-grade inflammation called inflammaging. Aging, likely via inflammaging, is also associated with the emergence of chronic diseases including cardiovascular and neurodegenerative diseases, cancer, and diabetes mellitus type 2. The origin of this inflammaging is not known with certainty, but several concurrent contributing factors have been suggested, such as aging-associated changes in the innate and adaptive immune response, chronic antigenic stimulation, the appearance of endogenous macromolecular changes, and the presence of senescent cells exhibiting a senescence-associated secretory phenotype. A better understanding of the multiple biological phenomena leading to these diseases via the immunosenescence associated with inflammaging provides a powerful target for interventions to increase the healthspan of elderly subjects.


REFERENCES

  1. Lipsky MS, King M. Biological theories of aging. Dis Mon. 2015; 61:460-6.

  2. Robert L, Fulop T (eds) Aging Facts and theories. Interdisciplinary Topics in Gerontology. Vol 38. Karger. 2014.

  3. Pawelec G, Goldeck D, Derhovanessian E. Inflammation, ageing and chronic disease. Curr Opin Immunol. 2014;29:23-8.

  4. Franceschi C, Campisi J. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J Gerontol A Biol Sci Med Sci. 2014;69(Suppl 1):S4-9.

  5. Seals DR, Justice JN, LaRocca TJ. Physiological geroscience: targeting function to increase healthspan and achieve optimal longevity. J Physiol. 2015 [Epub ahead of print].

  6. Kennedy BK, Berger SL, Brunet A, et al. Geroscience: linking aging to chronic disease. Cell. 2014;159:709-13.

  7. Seals DR, Melov S. Translational geroscience: emphasizing function to achieve optimal longevity. Aging (Albany NY). 2014;6:718-30.

  8. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 2013;153:1194-217.

  9. Solana R, Tarazona R, Gayoso I, Lesur O, Dupuis G, Fulop T. Innate immunosenescence: effect of aging on cells and receptors of the innate immune system in humans. Semin Immunol. 2012; 24:331-41.

  10. Montgomery RR, Shaw AC. Paradoxical changes in innate immunity in aging: recent progress and new directions. J Leukoc Biol. 2015;98:937-43.

  11. Castelo-Branco C, Soveral I. The immune system and aging: a review. Gynecol Endocrinol. 2014;30:16-22.

  12. Larbi A, Fulop T. From “truly naďve” to “exhausted senescent” T cells: when markers predict functionality. Cytometry A. 2014; 85:25-35.

  13. Fulop T, Dupuis G, Baehl S, et al. From inflamm-aging to immuneparalysis: a slippery slope during aging for immune-adaptation. Biogerontology. 2015. [Epub ahead of print].

  14. Fortin CF, McDonald PP, Lesur O, Fülöp T. Aging and neutrophils: there is still much to do. Rejuvenation Res. 2008;11:873-82.

  15. Juthani-Mehta M, Guo X, Shaw AC, et al. Innate immune responses in the neutrophils of community dwelling and nursing home elders. J Aging Sci. 2014;2.

  16. Visan I. Aging neutrophils. Nat Immunol. 2015;16:1113.

  17. Baëhl S, Garneau H, Le Page A, et al. Altered neutrophil functions in elderly patients during a 6-month follow-up period after a hip fracture. Exp Gerontol. 2015;65:58-68.

  18. Magrone T, Jirillo E. Disorders of innate immunity in human ageing and effects of nutraceutical administration. Endocr Metab Immune Disord Drug Targets. 2014;14:272-82.

  19. Hazeldine J, Harris P, Chapple IL, et al. Impaired neutrophil extracellular trap formation: a novel defect in the innate immune system of aged individuals. Aging Cell. 2014;13:690-8.

  20. Tseng CW, Liu GY. Expanding roles of neutrophils in aging hosts. Curr Opin Immunol. 2014;29:43-8.

  21. Qian F, Guo X, Wang X, et al. Reduced bioenergetics and toll-like receptor 1 function in human polymorphonuclear leukocytes in aging. Aging (Albany NY). 2014; 6:131-9.

  22. Fortin CF, Larbi A, Lesur O, Douziech N. Fulop T. Impairment of SHP-1 down-regulation in the lipid rafts of human neutrophils under GM-CSF stimulation contributes to their age-related, altered functions. J Leukoc Biol. 2006;79:1061-72.

  23. Khanfer R, Carroll D, Lord JM, Phillips AC. Reduced neutrophil superoxide production among healthy older adults in response to acute psychological stress. Int J Psychophysiol. 2012;86:238-44.

  24. Shaw AC, Goldstein DR, Montgomery RR. Age-dependent dysregulation of innate immunity. Nat Rev Immunol. 2013;13:875-87.

  25. Fulop T, Le Page A, Fortin C, Witkowski JM, Dupuis G, Larbi A. Cellular signaling in the aging immune system. Curr Opin Immunol. 2014;29:105-11.

  26. Sapey E, Greenwood H, Walton G, et al. Phosphoinositide 3-kinase inhibition restores neutrophil accuracy in the elderly: toward targeted treatments for immunosenescence. Blood. 2014;123: 239-48.

  27. Linton PJ, Thoman ML. Immunosenescence in monocytes, macrophages, and dendritic cells: lessons learned from the lung and heart. Immunol Lett. 2014;162:290-7.

  28. Nyugen J, Agrawal S, Gollapudi S, Gupta S. Impaired functions of peripheral blood monocyte subpopulations in aged humans. J Clin Immunol. 2010;30:806-13.

  29. Seidler S, Zimmermann HW, Bartneck M, Trautwein C, Tacke F. Age-dependent alterations of monocyte subsets and monocyterelated chemokine pathways in healthy adults. BMC Immunol. 2010;11:30.

  30. Zacca ER, Crespo MI, Acland RP, et al. Aging impairs the ability of conventional dendritic cells to cross-prime CD8+ T cells upon stimulation with a TLR7 ligand. PLoS One. 2015;10:e0140672.

  31. Pera A, Campos C,López N, et al. Immunosenescence: Implications for response to infection and vaccination in older people. Maturitas. 2015;82:50-5.

  32. Suchy D, Łabuzek K, Bułdak Ł, Szkudłapski D, Okopien´ B. Comparison of chosen activation markers of human monocytes/ macrophages isolated from the peripheral blood of young and elderly volunteers. Pharmacol Rep. 2014;66:759-65.

  33. Verschoor CP, Loukov D, Naidoo A, et al. Circulating TNF and mitochondrial DNA are major determinants of neutrophil phenotype in the advanced-age, frail elderly. Mol Immunol. 2015; 65:148-56.

  34. Li W. Phagocyte dysfunction, tissue aging and degeneration. Ageing Res Rev. 2013;12:1005-12.

  35. Meier J, Sturm A. The intestinal epithelial barrier: does it become impaired with age? Dig Dis. 2009;27:240-5.

  36. Valentini L, Ramminger S, Haas V, et al. Small intestinal permeability in older adults. Physiol Rep. 2014;2:e00281.

  37. Franceschi C, Bonafč M, Valensin S, et al. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci. 2000;908:244-54.

  38. Goto M. Inflammaging (inflammation + aging): a driving force for human aging based on an evolutionarily antagonistic pleiotropy theory? Biosci Trends. 2008;2:218-30.

  39. Palmer DB. The effect of age on thymic function. Front Immunol. 2013;4:316.

  40. Qi Q, Zhang DW, Weyand CM, Goronzy JJ. Mechanisms shaping the naďve T cell repertoire in the elderly - thymic involution or peripheral homeostatic proliferation? Exp Gerontol. 2014; 54:71-4.

  41. Appay V, Sauce D. Naive T cells: the crux of cellular immune aging? Exp Gerontol. 2014;54:90-3.

  42. Fülöp T, Larbi A, Pawelec G. Human T cell aging and the impact of persistent viral infections. Front Immunol. 2013;4:271.

  43. Pawelec G. Immunosenenescence: role of cytomegalovirus. Exp Gerontol. 2014;54:1-5.

  44. Nilsson BO, Ernerudh J, Johansson B, et al. Morbidity does not influence the T-cell immune risk phenotype in the elderly: findings in the Swedish NONA Immune Study using sample selection protocols. Mech Ageing Dev. 2003;124:469-76.

  45. Wikby A, Johansson B, Olsson J, Löfgren S, Nilsson BO, Ferguson F. Expansions of peripheral blood CD8 T-lymphocyte subpopulations and an association with cytomegalovirus seropositivity in the elderly: the Swedish NONA immune study. Exp Gerontol. 2002;37:445-53.

  46. Larbi A, Dupuis G, Khalil A, Douziech N, Fortin C, Fulop T. Differential role of lipid rafts in the functions of CD4+ and CD8+ human T lymphocytes with aging. Cell Signal. 2006;18:1017-30.

  47. Larbi A, Fortin C, Dupuis G, Berrougui H, Khalil A, Fulop T. Immunomodulatory role of high-density lipoproteins: impact on immunosenescence. Age (Dordr). 2014;36:9712.

  48. Larbi A, Pawelec G, Wong SC, Goldeck D, Tai JJ, Fülöp T. Impact of age on T cell signaling: a general defect or specific alterations? Ageing Res Rev. 2011;10:370-8.

  49. Goronzy JJ, Li G, Yu M, Weyand CM. Signaling pathways in aged T cells – a reflection of T cell differentiation, cell senescence and host environment. Semin Immunol. 2012;24:365-72.

  50. Le Page A, Fortin C, Garneau H, et al. Downregulation of inhibitory SRC homology 2 domain-containing phosphatase-1 (SHP-1) leads to recovery of T cell responses in elderly. Cell Commun Signal. 2014;12:2.

  51. Li G, Yu M, Lee WW, et al. Decline in miR-181a expression with age impairs T cell receptor sensitivity by increasing DUSP6 activity. Nat Med. 2012;18:1518-24.

  52. Giunta S. Exploring the complex relations between inflammation and aging (inflamm-aging): anti-inflamm-aging remodelling of inflamm- aging, from robustness to frailty. Inflamm Res. 2008; 57:558-63.

  53. Michaud M, Balardy L, Moulis G, et al. Proinflammatory cytokines, aging, and age-related diseases. J Am Med Dir Assoc. 2013;14:877-82.

  54. Franceschi C, Campisi J. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J Gerontol A Biol Sci Med Sci. 2014;69(Suppl 1):S4-9.

  55. Howcroft TK, Campisi J, Louis GB, et al. The role of inflammation in age-related disease. Aging (Albany NY). 2013;5:84-93.

  56. Castellani GC, Menichetti G, Garagnani P, et al. Systems medicine of inflammaging. Brief Bioinform. 2015. [Epub ahead of print].

  57. Laberge RM, Sun Y, Orjalo AV, et al. MTOR regulates the protumorigenic senescence-associated secretory phenotype by promoting IL1A translation. Nat Cell Biol. 2015;17:1049-61.

  58. Van Deursen JM. The role of senescent cells in ageing. Nature. 2014;509:439-46.

  59. Tchkonia T, Zhu Y, van Deursen J, Campisi J, Kirkland JL. Cellular senescence and the senescent secretory phenotype: therapeutic opportunities. J Clin Invest. 2013;123:966-72.

  60. Morrisette-Thomas V, Cohen AA, Fülöp T, et al. Inflamm-aging does not simply reflect increases in pro-inflammatory markers. Mech Ageing Dev. 2014;139:49-57.

  61. Jagger A, Shimojima Y, Goronzy JJ, Weyand CM. Regulatory T cells and the immune aging process: a mini-review. Gerontology. 2014;60:130-7.

  62. Bueno V, Sant’Anna OA, Lord JM. Ageing and myeloid-derived suppressor cells: possible involvement in immunosenescence and age-related disease. Age (Dordr). 2014;36:9729.

  63. Verschoor CP, Johnstone J, Millar J, et al. Blood CD33(+)HLADR(-) myeloid-derived suppressor cells are increased with age and a history of cancer. J Leukoc Biol. 2013;93:633-7.

  64. Fülöp T, Fortin C, Lesur O, et al. The innate immune system and aging: What is the contribution to immunosenescence? Open Longevity Science. 2012;6:121-32.

  65. Netea MG, Quintin J, van der Meer JW. Trained immunity: a memory for innate host defense. Cell Host Microbe. 2011;9:355-61.

  66. Bekkering S, Joosten LA, van der Meer JW, Netea MG, Riksen NP. The epigenetic memory of monocytes and macrophages as a novel drug target in atherosclerosis. Clin Ther. 2015;37:914-23

  67. Kyburz D, Karouzakis E, Ospelt C. Epigenetic changes: the missing link. Best Pract Res Clin Rheumatol. 2014;28:577-87.

  68. Kleinnijenhuis J, Quintin J, Preijers F, et al. Bacille Calmette- Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. Proc Natl Acad Sci U S A. 2012;109:17537-42.

  69. Quintin J, Saeed S, Martens JH, et al. Candida albicans infection affords protection against reinfection via functional reprogramming of monocytes. Cell Host Microbe. 2012;12:223-32.

  70. Ostuni R, Piccolo V, Barozzi I, et al. Latent enhancers activated by stimulation in differentiated cells. Cell. 2013;152:157-71.

  71. Cheng SC, Quintin J, Cramer RA, et al. mTOR- and HIF-1α- mediated aerobic glycolysis as metabolic basis for trained immunity. Science. 2014;345:1250684.

  72. Saeed S, Quintin J, Kerstens HH, et al. Epigenetic programming of monocyte-to-macrophage differentiation and trained innate immunity. Science. 2014;345:1251086.

  73. Heneka MT, Carson MJ, El Khoury J, et al. Neuroinflammation in Alzheimer’s disease Lancet Neurol. 2015;14:388-405.

  74. Deleidi M, Jäggle M, Rubino G. Immune aging, dysmetabolism, and inflammation in neurological diseases. Front Neurosci. 2015; 9:172.

  75. Vida C, González EM, De la Fuente M. Increase of oxidation and inflammation in nervous and immune systems with aging and anxiety. Curr Pharm Des. 2014;20:4656-78.

  76. ElAli A, Rivest S. Microglia in Alzheimer’s disease: A multifaceted relationship. Brain Behav Immun. 2015. [Epub ahead of print].

  77. Le Page A, Bourgade K, Lamoureux J, et al. NK cells are activated in amnestic mild cognitive impairment but not in mild alzheimer’s disease patients. J Alzheimers Dis. 2015;46:93-107.

  78. Larbi A, Pawelec G, Witkowski JM, et al. Dramatic shifts in circulating CD4 but not CD8 T cell subsets in mild Alzheimer’s disease. J Alzheimers Dis. 2009;17:91-103.

  79. Wu IC, Lin CC, Hsiung CA. Emerging roles of frailty and inflammaging in risk assessment of age-related chronic diseases in older adults: the intersection between aging biology and personalized medicine. Biomedicine (Taipei). 2015;5:1.

  80. McElhaney JE, Garneau H, Camous X, et al. Predictors of the antibody response to influenza vaccination in older adults with type 2 diabetes. BMJ Open Diabetes Res Care. 2015;3:e000140.

  81. Mori TA, Woodman RJ, Burke V, Puddey IB, Croft KD, Beilin LJ. Effect of eicosapentaenoic acid and docosahexaenoic acid on oxidative stress and inflammatory markers in treated-hypertensive type 2 diabetic subjects. Free Radic Biol Med. 2003; 35:772-81.

  82. Guarner V, Rubio-Ruiz ME. Low-grade systemic inflammation connects aging, metabolic syndrome and cardiovascular disease. Interdiscip Top Gerontol. 2015;40:99-106.

  83. Husain K, Hernandez W, Ansari RA, Ferder L. Inflammation, oxidative stress and renin angiotensin system in atherosclerosis. World J Biol Chem. 2015;6:209-17.

  84. Wick G, Perschinka H, Millonig G. Atherosclerosis as an autoimmune disease: an update. Trends Immunol. 2001;22:665-9.

  85. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868-74.

  86. Yu HT, Park S, Shin EC, Lee WW. T cell senescence and cardiovascular diseases. Clin Exp Med. 2015. [Epub ahead of print].

  87. Anker SD, von Haehling S. Inflammatory mediators in chronic heart failure: an overview. Heart. 2004;90:464-70.

  88. Moro-García MA, Echeverría A, Galán-Artímez MC, et al. Immunosenescence and inflammation characterize chronic heart failure patients with more advanced disease. Int J Cardiol. 2014; 174:590-9.

  89. Birks EJ, Felkin LE, Banner NR, Khaghani A, Barton PJ, Yacoub MH. Increased toll-like receptor 4 in the myocardium of patients requiring left ventricular assist devices. J Heart Lung Transplant. 2004;23:228-35.

  90. Foldes G, von Haehling S, Okonko DO, Jankowska EA, Poole- Wilson PA, Anker SD. Fluvastatin reduces increased blood monocyte Toll-like receptor 4 expression in whole blood from patients with chronic heart failure. Int J Cardiol. 2008;124:80-5.




2020     |     www.medigraphic.com